Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SC 0062

Next Previous
Drug Profile

SC 0062

Alternative Names: SC-0062

Latest Information Update: 30 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocity Biopharmaceutics
  • Class Small molecules; Urologics
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III IgA nephropathy
  • Phase II Diabetic nephropathies

Most Recent Events

  • 25 Jun 2025 SC 0062 receives Breakthrough Therapy status for Diabetic nephropathies in China
  • 23 Feb 2025 Updated efficacy and adverse events data from the phase II 2-SUCCEED trial in IgA nephropathy and Diabetic nephropathies released by Biocity Biopharmaceutics
  • 17 Feb 2025 Phase-III clinical trials in IgA nephropathy in China (PO) (NCT06819826)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top